|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ladabaum U, Dominitz JA, Kahi C and Schoen
RE: Strategies for colorectal cancer screening. Gastroenterology.
158:418–432. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Han L, Dai W, Mo S, Xiang W, Li Q, Xu Y,
Cai G and Wang R: Nomogram of conditional survival probability of
long-term survival for metastatic colorectal cancer: A real-world
data retrospective cohort study from SEER database. Int J Surg.
92:1060132021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kahi CJ, Boland CR, Dominitz JA,
Giardiello FM, Johnson DA, Kaltenbach T, Lieberman D, Levin TR,
Robertson DJ and Rex DK: Colonoscopy surveillance after colorectal
cancer resection: Recommendations of the US multi-society task
force on colorectal cancer. Am J Gastroenterol. 111:337–346; quiz
347. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Biller LH and Schrag D: Diagnosis and
treatment of metastatic colorectal cancer: A review. JAMA.
325:669–685. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Siegel RL, Miller KD, Sauer AG, Fedewa SA,
Butterly LF, Anderson JC, Cercek A, Smith RA and Jemal A:
Colorectal cancer statistics, 2020. CA Cancer J Clin. 70:145–164.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Osseis M, Nehmeh WA, Rassy N, Derienne J,
Noun R, Salloum C, Rassy E, Boussios S and Azoulay D: Surgery for
T4 colorectal cancer in older patients: Determinants of outcomes. J
Pers Med. 12:15342022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chan TA, Yarchoan M, Jaffee E, Swanton C,
Quezada SA, Stenzinger A and Peters S: Development of tumor
mutation burden as an immunotherapy biomarker: Utility for the
oncology clinic. Ann Oncol. 30:44–56. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Samstein RM, Lee CH, Shoushtari AN,
Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ,
Omuro A, et al: Tumor mutational load predicts survival after
immunotherapy across multiple cancer types. Nat Genet. 51:202–206.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Riley RS, June CH, Langer R and Mitchell
MJ: Delivery technologies for cancer immunotherapy. Nat Rev Drug
Discov. 18:175–196. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Overman MJ, Lonardi S, Wong KYM, Lenz HJ,
Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill
A, et al: Durable clinical benefit with nivolumab plus ipilimumab
in DNA mismatch repair-deficient/microsatellite instability-high
metastatic colorectal cancer. J Clin Oncol. 36:773–779. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Overman MJ, McDermott R, Leach JL, Lonardi
S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al:
Nivolumab in patients with metastatic DNA mismatch repair-deficient
or microsatellite instability-high colorectal cancer (CheckMate
142): An open-label, multicentre, phase 2 study. Lancet Oncol.
18:1182–1191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ganesh K, Stadler ZK, Cercek A, Mendelsohn
RB, Shia J, Segal NH and Diaz LA Jr: Immunotherapy in colorectal
cancer: Rationale, challenges and potential. Nat Rev Gastroenterol
Hepatol. 16:361–375. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Adeleke S, Haslam A, Choy A, Diaz-Cano S,
Galante JR, Mikropoulos C and Boussios S: Microsatellite
instability testing in colorectal patients with Lynch syndrome:
Lessons learned from a case report and how to avoid such pitfalls.
Per Med. 19:277–286. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Krenkel O and Tacke F: Liver macrophages
in tissue homeostasis and disease. Nat Rev Immunol. 17:306–321.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ruffell B and Coussens LM: Macrophages and
therapeutic resistance in cancer. Cancer Cell. 27:462–472. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mantovani A, Bottazzi B, Colotta F,
Sozzani S and Ruco L: The origin and function of tumor-associated
macrophages. Immunol Today. 13:265–270. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ginhoux F, Schultze JL, Murray PJ, Ochando
J and Biswas SK: New insights into the multidimensional concept of
macrophage ontogeny, activation and function. Nat Immunol.
17:34–40. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mantovani A, Marchesi F, Malesci A, Laghi
L and Allavena P: Tumour-associated macrophages as treatment
targets in oncology. Nat Rev Clin Oncol. 14:399–416. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pan Y, Yu Y, Wang X and Zhang T:
Tumor-associated macrophages in tumor immunity. Front Immunol.
11:5830842020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
An Y and Yang Q: Tumor-associated
macrophage-targeted therapeutics in ovarian cancer. Int J Cancer.
149:21–30. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jung KY, Cho SW, Kim YA, Kim D, Oh BC,
Park DJ and Park YJ: Cancers with higher density of
tumor-associated macrophages were associated with poor survival
rates. J Pathol Transl Med. 49:318–324. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yeung OW, Lo CM, Ling CC, Qi X, Geng W, Li
CX, Ng KT, Forbes SJ, Guan XY, Poon RTP, et al: Alternatively
activated (M2) macrophages promote tumour growth and invasiveness
in hepatocellular carcinoma. J Hepatol. 62:607–616. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou SL, Zhou ZJ, Hu ZQ, Huang XW, Wang Z,
Chen EB, Fan J, Cao Y, Dai Z and Zhou J: Tumor-associated
neutrophils recruit macrophages and T-regulatory cells to promote
progression of hepatocellular carcinoma and resistance to
sorafenib. Gastroenterology. 150:1646–1658.e1617. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gubin MM, Esaulova E, Ward JP, Malkova ON,
Runci D, Wong P, Noguchi T, Arthur CD, Meng W, Alspach E, et al:
High-dimensional analysis delineates myeloid and lymphoid
compartment remodeling during successful immune-checkpoint cancer
therapy. Cell. 175:1014–1030.e1019. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Molgora M, Esaulova E, Vermi W, Hou J,
Chen Y, Luo J, Brioschi S, Bugatti M, Omodei AS, Ricci B, et al:
TREM2 modulation remodels the tumor myeloid landscape enhancing
Anti-PD-1 immunotherapy. Cell. 182:886–900.e817. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiong H, Mittman S, Rodriguez R,
Moskalenko M, Pacheco-Sanchez P, Yang Y, Nickles D and Cubas R:
Anti-PD-L1 treatment results in functional remodeling of the
macrophage compartment. Cancer Res. 79:1493–1506. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Boussios S, Ozturk MA, Moschetta M,
Karathanasi A, Zakynthinakis-Kyriakou N, Katsanos KH, Christodoulou
DK and Pavlidis N: The developing story of predictive biomarkers in
colorectal cancer. J Pers Med. 9:122019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen H, Ye F and Guo G: Revolutionizing
immunology with single-cell RNA sequencing. Cell Mol Immunol.
16:242–249. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liang L, Yu J, Li J, Li N, Liu J, Xiu L,
Zeng J, Wang T and Wu L: Integration of scRNA-Seq and bulk RNA-Seq
to analyse the heterogeneity of ovarian cancer immune cells and
establish a molecular risk model. Front Oncol. 11:7110202021.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bao X, Shi R, Zhao T, Wang Y, Anastasov N,
Rosemann M and Fang W: Integrated analysis of single-cell RNA-seq
and bulk RNA-seq unravels tumour heterogeneity plus M2-like
tumour-associated macrophage infiltration and aggressiveness in
TNBC. Cancer Immunol Immunother. 70:189–202. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen Z, Yu M, Yan J, Guo L, Zhang B, Liu
S, Lei J, Zhang W, Zhou B, Gao J, et al: PNOC expressed by B cells
in cholangiocarcinoma was survival related and LAIR2 could be a T
cell exhaustion biomarker in tumor microenvironment:
Characterization of immune microenvironment combining single-cell
and bulk sequencing technology. Front Immunol. 12:6472092021.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li X, Liao Z, Deng Z, Chen N and Zhao L:
Combining bulk and single-cell RNA-sequencing data to reveal gene
expression pattern of chondrocytes in the osteoarthritic knee.
Bioengineered. 12:997–1007. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shi L, Mao H and Ma J: Integrated analysis
of tumor-associated macrophages and M2 macrophages in CRC:
Unraveling molecular heterogeneity and developing a novel risk
signature. BMC Med Genomics. 17:1452024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Khaliq AM, Erdogan C, Kurt Z, Turgut SS,
Grunvald MW, Rand T, Khare S, Borgia JA, Hayden DM, Pappas SG, et
al: Refining colorectal cancer classification and clinical
stratification through a single-cell atlas. Genome Biol.
23:1132022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Langfelder P and Horvath S: WGCNA: An R
package for weighted correlation network analysis. BMC
Bioinformatics. 9:5592008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Brunet JP, Tamayo P, Golub TR and Mesirov
JP: Metagenes and molecular pattern discovery using matrix
factorization. Proc Natl Acad Sci USA. 101:4164–4169. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Newman AM, Liu CL, Green MR, Gentles AJ,
Feng W, Xu Y, Hoang CD, Diehn M and Alizadeh AA: Robust enumeration
of cell subsets from tissue expression profiles. Nat Methods.
12:453–457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Charoentong P, Finotello F, Angelova M,
Mayer C, Efremova M, Rieder D, Hackl H and Trajanoski Z: Pan-cancer
immunogenomic analyses reveal genotype-immunophenotype
relationships and predictors of response to checkpoint blockade.
Cell Rep. 18:248–262. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mariathasan S, Turley SJ, Nickles D,
Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita
JL, Cubas R, et al: TGFβ attenuates tumour response to PD-L1
blockade by contributing to exclusion of T cells. Nature.
554:544–548. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ayers M, Lunceford J, Nebozhyn M, Murphy
E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran
V, et al: IFN-γ-related mRNA profile predicts clinical response to
PD-1 blockade. J Clin Invest. 127:2930–2940. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jiang L, Liu JY, Shi Y, Tang B, He T, Liu
JJ, Fan JY, Wu B, Xu XH, Zhao YL, et al: MTMR2 promotes invasion
and metastasis of gastric cancer via inactivating IFNγ/STAT1
signaling. J Exp Clin Cancer Res. 38:2062019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Reiner A, Spona J, Reiner G, Schemper M,
Kolb R, Kwasny W, Függer R, Jakesz R and Holzner JH: Estrogen
receptor analysis on biopsies and fine-needle aspirates from human
breast carcinoma. Correlation of biochemical and
immunohistochemical methods using monoclonal antireceptor
antibodies. Am J Pathol. 125:443–449. 1986.PubMed/NCBI
|
|
44
|
Snyder A, Makarov V, Merghoub T, Yuan J,
Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et
al: Genetic basis for clinical response to CTLA-4 blockade in
melanoma. N Engl J Med. 371:2189–2199. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhou KI, Hanks BA and Strickler JH:
Management of microsatellite instability high (MSI-H)
gastroesophageal adenocarcinoma. J Gastrointest Cancer. 55:483–496.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wu Z, Huang X, Han X, Li Z, Zhu Q, Yan J,
Yu S, Jin Z, Wang Z, Zheng Q and Wang Y: The chemokine CXCL9
expression is associated with better prognosis for colorectal
carcinoma patients. Biomed Pharmacother. 78:8–13. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sathe A, Mason K, Grimes SM, Zhou Z, Lau
BT, Bai X, Su A, Tan X, Lee H, Suarez CJ, et al: Colorectal cancer
metastases in the liver establish immunosuppressive spatial
networking between tumor-associated SPP1+ macrophages and
fibroblasts. Clin Cancer Res. 29:244–260. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cabrero-de Las Heras S, Hernández-Yagüe X,
González A, Losa F, Soler G, Bugés C, Baraibar I, Esteve A,
Pardo-Cea MÁ, Ree AH, et al: Changes in serum CXCL13 levels are
associated with outcomes of colorectal cancer patients undergoing
first-line oxaliplatin-based treatment. Biomed Pharmacother.
176:1168572024. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ding L, Getz G, Wheeler DA, Mardis ER,
McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan
MB, et al: Somatic mutations affect key pathways in lung
adenocarcinoma. Nature. 455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Langnaese K, Colleaux L, Kloos DU, Fontes
M and Wieacker P: Cloning of Z39Ig, a novel gene with
immunoglobulin-like domains located on human chromosome X. Biochim
Biophys Acta. 1492:522–525. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Small AG, Al-Baghdadi M, Quach A, Hii C
and Ferrante A: Complement receptor immunoglobulin: A control point
in infection and immunity, inflammation and cancer. Swiss Med Wkly.
146:w143012016.PubMed/NCBI
|
|
52
|
Helmy KY, Katschke KJ Jr, Gorgani NN,
Kljavin NM, Elliott JM, Diehl L, Scales SJ, Ghilardi N and van
Lookeren Campagne M: CRIg: A macrophage complement receptor
required for phagocytosis of circulating pathogens. Cell.
124:915–927. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Chow A, Schad S, Green MD, Hellmann MD,
Allaj V, Ceglia N, Zago G, Shah NS, Sharma SK, Mattar M, et al:
Tim-4+ cavity-resident macrophages impair anti-tumor
CD8+ T cell immunity. Cancer Cell. 39:973–988.e979.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Li J, Diao B, Guo S, Huang X, Yang C, Feng
Z, Yan W, Ning Q, Zheng L, Chen Y and Wu Y: VSIG4 inhibits
proinflammatory macrophage activation by reprogramming
mitochondrial pyruvate metabolism. Nat Commun. 8:13222017.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Vogt L, Schmitz N, Kurrer MO, Bauer M,
Hinton HI, Behnke S, Gatto D, Sebbel P, Beerli RR, Sonderegger I,
et al: VSIG4, a B7 family-related protein, is a negative regulator
of T cell activation. J Clin Invest. 116:2817–2826. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Srirussamee K, Mobini S, Cassidy NJ and
Cartmell SH: Direct electrical stimulation enhances osteogenesis by
inducing Bmp2 and Spp1 expressions from macrophages and
preosteoblasts. Biotechnol Bioeng. 116:3421–3432. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wei J, Marisetty A, Schrand B,
Gabrusiewicz K, Hashimoto Y, Ott M, Grami Z, Kong LY, Ling X,
Caruso H, et al: Osteopontin mediates glioblastoma-associated
macrophage infiltration and is a potential therapeutic target. J
Clin Invest. 129:137–149. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Su X, Xu BH, Zhou DL, Ye ZL, He HC, Yang
XH, Zhang X, Liu Q, Ma JJ, Shao Q, et al: Polymorphisms in
matricellular SPP1 and SPARC contribute to susceptibility to
papillary thyroid cancer. Genomics. 112:4959–4967. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Chen P, Zhao D, Li J, Liang X, Li J, Chang
A, Henry VK, Lan Z, Spring DJ, Rao G, et al: Symbiotic
macrophage-glioma cell interactions reveal synthetic lethality in
PTEN-null glioma. Cancer Cell. 35:868–884.e866. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhang Y, Du W, Chen Z and Xiang C:
Upregulation of PD-L1 by SPP1 mediates macrophage polarization and
facilitates immune escape in lung adenocarcinoma. Exp Cell Res.
359:449–457. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Hurley PJ, Hughes RM, Simons BW, Huang J,
Miller RM, Shinder B, Haffner MC, Esopi D, Kimura Y, Jabbari J, et
al: Androgen-regulated SPARCL1 in the tumor microenvironment
inhibits metastatic progression. Cancer Res. 75:4322–4334. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Naschberger E, Liebl A, Schellerer VS,
Schütz M, Britzen-Laurent N, Kölbel P, Schaal U, Haep L,
Regensburger D, Wittmann T, et al: Matricellular protein SPARCL1
regulates tumor microenvironment-dependent endothelial cell
heterogeneity in colorectal carcinoma. J Clin Invest.
126:4187–4204. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zhao SJ, Jiang YQ, Xu NW, Li Q, Zhang Q,
Wang SY, Li J, Wang YH, Zhang YL, Jiang SH, et al: SPARCL1
suppresses osteosarcoma metastasis and recruits macrophages by
activation of canonical WNT/β-catenin signaling through
stabilization of the WNT-receptor complex. Oncogene. 37:1049–1061.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wu L, Sun S, Qu F, Sun M, Liu X, Sun Q,
Cheng L, Zheng Y and Su G: CXCL9 influences the tumor immune
microenvironment by stimulating JAK/STAT pathway in triple-negative
breast cancer. Cancer Immunol Immunother. 72:1479–1492. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Yang M, Lu J, Zhang G, Wang Y, He M, Xu Q,
Xu C and Liu H: CXCL13 shapes immunoactive tumor microenvironment
and enhances the efficacy of PD-1 checkpoint blockade in high-grade
serous ovarian cancer. J Immunother Cancer. 9:e0011362021.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Marcovecchio PM, Thomas G and
Salek-Ardakani S: CXCL9-expressing tumor-associated macrophages:
New players in the fight against cancer. J Immunother Cancer.
9:e0020452021. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Xie Y, Chen Z, Zhong Q, Zheng Z, Chen Y,
Shangguan W, Zhang Y, Yang J, Zhu D and Xie W: M2 macrophages
secrete CXCL13 to promote renal cell carcinoma migration, invasion,
and EMT. Cancer Cell Int. 21:6772021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zhao S, Mi Y, Guan B, Zheng B, Wei P, Gu
Y, Zhang Z, Cai S, Xu Y, Li X, et al: Tumor-derived exosomal
miR-934 induces macrophage M2 polarization to promote liver
metastasis of colorectal cancer. J Hematol Oncol. 13:1562020.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Huang D, Sun W, Zhou Y, Li P, Chen F, Chen
H, Xia D, Xu E, Lai M, Wu Y and Zhang H: Mutations of key driver
genes in colorectal cancer progression and metastasis. Cancer
Metastasis Rev. 37:173–187. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Popat S, Hubner R and Houlston RS:
Systematic review of microsatellite instability and colorectal
cancer prognosis. J Clin Oncol. 23:609–618. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Ward R, Meagher A, Tomlinson I, O'Connor
T, Norrie M, Wu R and Hawkins N: Microsatellite instability and the
clinicopathological features of sporadic colorectal cancer. Gut.
48:821–829. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
García-Marín R, Reda S, Riobello C, Cabal
VN, Suárez-Fernández L, Vivanco B, Álvarez-Marcos C, López F,
Llorente JL and Hermsen MA: Prognostic and therapeutic implications
of immune classification by CD8(+) tumor-infiltrating lymphocytes
and PD-L1 expression in sinonasal squamous cell carcinoma. Int J
Mol Sci. 22:69262021. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Zhang Y, Wang X, Shi M, Song Y, Yu J and
Han S: Programmed death ligand 1 and tumor-infiltrating
CD8+ T lymphocytes are associated with the clinical
features in meningioma. BMC Cancer. 22:11712022. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Chen YP, Zhang Y, Lv JW, Li YQ, Wang YQ,
He QM, Yang XJ, Sun Y, Mao YP, Yun JP, et al: Genomic analysis of
tumor microenvironment immune types across 14 solid cancer types:
Immunotherapeutic implications. Theranostics. 7:3585–3594. 2017.
View Article : Google Scholar : PubMed/NCBI
|
